STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)

NCT ID: NCT01008085

Last Updated: 2011-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2010-12-31

Brief Summary

Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.

Detailed Description

Stent strut malapposition and stent underexpansion are a common phenomenon in AMI as a result of the changing anatomy after an AMI has occurred (thrombus dissolution, resolution of spasm) with the traditional balloon-expandable stent treatment. A self-expanding stent might lead to better stent strut apposition as it follows the contours of the vessel wall due to its self-expanding properties. This might result into better long term clinical outcomes like lower thrombosis rates.

Conditions

STEMI

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Self-expanding stent

Stentys stent

Group Type: EXPERIMENTAL

Stentys coronary stent

Intervention Type: DEVICE

Self-expanding Nitinol stent

Balloon-expandable stent

VISION/Driver

Group Type: ACTIVE_COMPARATOR

Balloon-expandable stent

Intervention Type: DEVICE

VISION/Driver

Interventions

Stentys coronary stent

Self-expanding Nitinol stent

Intervention Type: DEVICE

Balloon-expandable stent

VISION/Driver

Intervention Type: DEVICE

Other Intervention Names

Self-expanding stent; VISION/Driver

Eligibility Criteria

Inclusion Criteria

1. Subject 18 years old.

2. Acute Myocardial Infarction defined as presence of at least two of the three items below:

1. Detection of rise of cardiac biomarkers with a least one value above the 99th percentile of the upper reference limit (URL)

2. Symptoms of ischaemia (chest pain) >20 minutes

3. ECG changes indicative of new ischaemia: new ST-T changes (ST deviation ≥0.2mV precordial leads and/or ≥0.1mV limb leads) or new LBBB)

3. Reperfusion expected to be achieved within 12 hours from the onset of symptoms

4. Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure.

5. Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone.

6. Acceptable candidate for coronary artery bypass graft (CABG) surgery.

7. Male or non-pregnant female subject.

1. Reference vessel diameter >2.5mm and <4.0mm by visual estimate.

2. Target lesion <30mm in length by visual estimate

Exclusion Criteria

1. Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.

2. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to the procedure.

3. Target vessel supplied by by-pass vessel

4. Patients on anticoagulation therapy (Coumadin)

5. Patient received thrombolytic therapy.

6. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a previously implanted stent

7. Cardiogenic shock

8. Any previous stent placement within 10mm (proximal or distal) of the target lesion.

9. Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.

10. Concurrent medical condition with a life expectancy of less than 6 months.

11. Left ventricular ejection fraction (LVEF) <30% at the most recent evaluation.

12. Cerebrovascular accident or transient ischemic attack in the last 6 months.

13. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.

14. Known serum creatinine level >2.5mg/dl or presence or history of renal failure

1. Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).

2. Target vessel is excessively tortuous (two bends >90˚ to reach the target lesion).

3. Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX.

4. Target lesion is severely calcified.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stentys

INDUSTRY

Sponsor Role: lead

Responsible Party

STENTYS

Principal Investigators

Stefan Verheye, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

ZNA, Middelheim, Belgium

Locations

C. Spaulding

Paris, , France

Countries

France

References

Nakatani S, Onuma Y, Ishibashi Y, Karanasos A, Regar E, Garcia-Garcia HM, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, Spaulding C, Reczuch K, La Manna A, Spaargaren R, Capodanno D, Van Langenhove G, Verheye S, Serruys PW, van Geuns RJ. Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention. 2015 Dec;11(8):885-94. doi: 10.4244/EIJY15M11_01.

Reference Type: DERIVED

PMID: 26549374 (View on PubMed)

van Geuns RJ, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, Spaulding C, Reczuch K, La Manna A, Spaargaren R, Garcia-Garcia HM, Regar E, Capodanno D, Van Langenhove G, Verheye S. Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012 Dec;5(12):1209-19. doi: 10.1016/j.jcin.2012.08.016.

Reference Type: DERIVED

PMID: 23257368 (View on PubMed)

Other Identifiers

ST2009-02

Identifier Type: -

Identifier Source: org_study_id